Related Experiment Videos
Ototoxicity of tobramycin: a clinical overview
Abstract:
In a survey of data on 3,506 patients treated with tobramycin, the 21 cases of drug-related ototoxicity are reported and reviewed. In seven patients the effects were auditory only, in nine vestibular only, and in five both auditory and vestibular. Effects subsided in 14 of the 18 patients who were available for monitoring after therapy. High-frequency audiometric losses persisted in three patients, and a hearing decrease persisted in one. In only one of the three patients did audiometric losses exceed 40 decibels. The patients with drug-related ototoxicity were compared to a group of 49 patients for whom both audiometric testing (before and after therapy) and clinical observation showed that no ototoxic reactions had occurred. Preexisting renal impairment, prior and/or concomitant therapy with other possibly ototoxic drugs, and therapy for 10 days or more with a dose of greater than 3 mg/kg per day were found to be associated with ototoxicity.
Insights
This study reviewed 21 tobramycin-related ototoxicity cases in 3,506 patients. While most cases resolved, risk factors like kidney issues and prolonged high-dose tobramycin therapy increased the likelihood of hearing or balance problems.
Area of Science:
- Ototoxicity
- Pharmacology
- Audiology
Background:
- Aminoglycoside antibiotics, such as tobramycin, are crucial for treating severe bacterial infections.
- Ototoxicity is a known, albeit infrequent, adverse effect associated with aminoglycoside use.
- Understanding the incidence and risk factors for tobramycin-induced ototoxicity is vital for patient safety.
Purpose of the Study:
- To report and review cases of drug-related ototoxicity in patients treated with tobramycin.
- To identify clinical factors associated with the development of tobramycin-induced ototoxicity.
- To compare patients with ototoxicity to a control group without ototoxic reactions.
Main Methods:
- Retrospective review of 3,506 patient cases treated with tobramycin.
- Detailed analysis of 21 identified cases of drug-related ototoxicity.
- Audiometric testing and clinical observation for assessment of auditory and vestibular function.
- Comparison of ototoxic cases with a control group of 49 patients without ototoxicity.
Main Results:
- Twenty-one cases of tobramycin-related ototoxicity were identified.
- Ototoxic effects included auditory, vestibular, or combined impairments.
- Most effects (14/18) resolved after therapy, but some patients experienced persistent high-frequency hearing loss.
- Risk factors associated with ototoxicity included preexisting renal impairment, concurrent ototoxic drug use, and prolonged high-dose tobramycin therapy (>3 mg/kg/day for ≥10 days).
Conclusions:
- Tobramycin can cause auditory and vestibular ototoxicity, although effects often resolve.
- Identifying patients with risk factors such as renal impairment and concomitant ototoxic medication is crucial for monitoring.
- Careful consideration of dosage and duration of tobramycin therapy is recommended to minimize ototoxic risks.